Regulation of Elemental Impurities in Medicines: Implementation of ICH Q3D and Analytical Challenges

Cvetanovska Gjorgjevska, Marija and Arsova-Sarafinovska, Zorica (2015) Regulation of Elemental Impurities in Medicines: Implementation of ICH Q3D and Analytical Challenges. Knowledge – International Journal, 73 (4). pp. 713-714. ISSN 2545-4439

[thumbnail of REGULATION+OF+ELEMENTAL+IMPURITIES+IN+MEDICINES+IMPLEMENTATION+OF+ICH+Q3D+AND+ANALYTICAL+CHALLENGES.pdf] Text
REGULATION+OF+ELEMENTAL+IMPURITIES+IN+MEDICINES+IMPLEMENTATION+OF+ICH+Q3D+AND+ANALYTICAL+CHALLENGES.pdf - Published Version

Download (854kB)

Abstract

The purpose of this study is to emphasize the importance of controlling elemental impurities in pharmaceutical products to protect patient health and ensure product quality. Medicines must be as pure as possible because the presence of elemental impurities, which are traces of metals introduced during production, purification, transportation, or storage, can have toxic effects and pose significant health risks. The methodology used in this study involved a detailed review of international guidelines, published research, and analytical techniques related to detecting and regulating elemental impurities. Special focus was placed on the guideline of the International Council for Harmonization on elemental impurity control, which establishes toxicologically based limits for permitted daily exposure. This guideline promotes a scientific and risk-based approach to impurity management. The results show that adherence to Good Manufacturing Practice and thoughtful process design can reduce, but not completely eliminate, elemental impurities. Modern analytical technologies such as inductively coupled plasma mass spectrometry and atomic absorption spectroscopy provide more accurate detection and quantification than classical heavy metal tests. The conclusions highlight that understanding the potential sources of contamination — including raw materials, equipment, water, and packaging — is essential to maintaining safe impurity levels. It is recommended that pharmaceutical manufacturers develop and apply thorough risk assessment strategies throughout production. Continuous monitoring of impurity levels and strict compliance with international standards are crucial for ensuring safety. Additional data from reviewed literature confirm that a systematic, science-driven approach significantly improves impurity control. Such strategies enhance both the reliability of pharmaceutical products and the safety of patients. Ultimately, effective control of elemental impurities represents a cornerstone of modern pharmaceutical quality assurance.

Item Type: Article
Subjects: Medical and Health Sciences > Health sciences
Medical and Health Sciences > Other medical sciences
Divisions: Faculty of Medical Science
Depositing User: Zorica Arsova Sarafinovska
Date Deposited: 24 Aug 2026 07:44
Last Modified: 24 Aug 2026 07:44
URI: https://eprints.ugd.edu.mk/id/eprint/38900

Actions (login required)

View Item
View Item